11th IAS Conference on HIV Science (IAS 2021), Berlin, Germany, 18-21 July 2021

第 11 届 IAS HIV 科学会议 (IAS 2021)，德国柏林，2021 年 7 月 18-21 日

• 批准号: 10254560
• 负责人: Christopher C. Beyrer
• 金额: $ 75万
• 依托单位: IAS
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-06-09 至 2022-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10254560
• 关键词: 2019-nCoV; AIDS prevention; AIDS/HIV problem; Acquired Immunodeficiency Syndrome; Address; Adherence; Adolescent and Young Adult; Adult; Affect; Africa; Africa South of the Sahara; Age; Aging; Antiviral Agents; Basic Science; Behavioral; Behavioral Sciences; Berlin; COVID-19; COVID-19 pandemic; COVID-19 vaccine; Caring; Child; Childhood; Chronic; Cities; Clinical; Clinical Research; Clinical Sciences; Communities; Complex; Contraceptive Agents; Contraceptive methods; Counseling; Country; Coupled; Data; Development; Discrimination; Disease; Disease Progression; Disease remission; Eastern Europe; Emergency response; Ensure; Epidemic; Europe; Failure; Fatigue; Financial Support; Formulation; Fostering; Futility; Gays; Germany; HIV; HIV Vaccine Trials Network; HIV vaccine; HIV/TB; Health; Health Resources; Health Services Accessibility; Health system; Heart; Homophobia; Human; Human immunodeficiency virus test; Immunology; Incidence; Incidence Study; Infant; Infection; Injectable; Injecting drug user; Integrase Inhibitors; International AIDS; Interruption; Intervention; Knowledge; Leadership; Life; Minority; Modality; Morbidity - disease rate; Multi-Drug Resistance; Opiate Addiction; Outcome; Pathogenesis; Patients; Persons; Population; Positioning Attribute; Prevention; Prevention Research; Prevention approach; Prevention program; Preventive vaccine; Public Health; Recording of previous events; Regimen; Relative Risks; Reporting; Research; Research Personnel; Resources; Rights; Risk Reduction; SARS-CoV-2 infection; Safety; Science; Scientist; Social Sciences; Structure; Technology; Testing; Ukraine; Uncertainty; Update; Vaccines; Variant; Viral hepatitis; Virus Diseases; War; Woman; Work; base; body system; clinical care; co-infection; community engagement; comorbidity; density; efficacy trial; implementation science; improved; innovation; insight; interdisciplinary collaboration; low and middle-income countries; marginalized population; men; men who have sex with men; mortality; multidisciplinary; novel; pandemic disease; patient oriented; person centered; pill; pre-exposure prophylaxis; precision medicine; preventive intervention; programs; public health emergency; racial and ethnic disparities; reproductive; response; social stigma; social structure; symposium; synergism; tool; transgender women; transmission process; transphobia; treatment program; virology; virtual; virtual delivery

Project Summary The scientific and public health response against HIV/AIDS in the past four decades has been remarkable and unprecedented. Yet HIV transmission continues in many populations at unacceptably high rates despite testing and treatment availability, largely driven by stigma and discrimination and other social and structural determinants. IAS 2021 will be the key global scientific convening to review progress against remaining challenges in controlling the epidemic. Significant new insights that are expected to be shared at IAS 2021 include basic work on virology, immunology and HIV pathogenesis with a continued focus on the functional cure/remission agenda. Clinical research in HIV is entering a new era of longer acting and injectable formulations which will be highlighted at IAS 2021, along with the remaining challenges of adherence, pill fatigue, and multi-drug resistant variants. Pediatric clinical care issues will be a further key topic where the advances in newer integrase inhibitor-based regimens for infants and children will be a primary focus. In the prevention field, the finding of superiority for long-acting injectable cabotegravir as PrEP marks the beginning of a new era, with further evidence expected in this regard at IAS 2021, along with early data on the co-formulations of long-acting injectables with other products for contraception, opioid dependence, and other health conditions. In the implementation science field innovative testing, prevention, treatment, and surveillance modalities will feature prominently at IAS 2021. Finally, the COVID-19 pandemic is expected to be among the defining themes across all scientific tracks against the background of treatment interruptions worldwide and the many remaining uncertainties regarding HIV/SARS- CoV-2 interactions. While the IAS is making parallel provisions for shifting to a fully virtual delivery format if mandated by the state of the COVID-19 pandemic, IAS 2021 is planned to take place in Berlin from 18-21 July 2021, with a strong virtual presence to ensure broad access (expected attendance of 6,000 delegates). It will provide a critical platform for HIV science to re-convene in a country now characterized by a celebration of diversity and zero discrimination. Berlin is at the heart of Europe, with close connectivity to the most HIV-affected region in Europe—Central and Eastern Europe, in particular Ukraine, and the Russian Federation, where, in marked contrast to Germany, rights-based approaches to HIV programming are constantly challenged. Specific aims of IAS 2021 are to: 1. Accelerate basic science and clinical innovation for the development and application of person-centered, precision medicine for HIV, including pathogenesis, transmission, vaccines, remission and a functional cure. 2. Advance inter-disciplinary collaboration in clinical research to improve integrated care across all life stages and accelerate updates to treatment guidance especially for low and middle-income countries, infected children, persons with HIV, TB, viral hepatitis and COVID-19 infection; 3. Strengthen HIV prevention research to improve biomedical, behavioral and structural interventions and the integration of new tools, including long-acting injectable prevention technologies in prevention programs for those in need; 4. Advance core components of the implementation science agenda across the HIV prevention-to-care cascade in the COVID-19 era, including aspects of integration and approaches for meaningful community engagement and resourcing health systems; 5. Address HIV vulnerability and determinants of disease progression among key and marginalized populations, including novel interventions and implementation science to reduce stigma and discrimination, including intersectional stigmas of HIV, other diseases, homophobia, transphobia, and ethnic and racial disparities. The scientific program will consist of four tracks: Track A – Basic Science; Track B – Clinical Science; Track C – Prevention Science; and Track D – Social, Behavioral, and Implementation Science. Cross-cutting aspects will be covered in plenary talks that also connect the scientific tracks with community and leadership perspectives, and bridging sessions will cut across at least two of the tracks to provide opportunities for multi-disciplinary dialogues. The participation of young researchers, basic scientists and researchers in related fields such as non- communicable diseases will be strengthened by active solicitation of relevant science and the provision of specific financial support, in addition to increased remote-access options.

项目摘要 在过去的40年里，针对艾滋病毒/艾滋病的科学和公共卫生对策卓有成效， 史无前例。然而，尽管进行了检测，艾滋病毒在许多人群中的传播率仍高得令人无法接受 和治疗的可获得性，主要是由耻辱和歧视以及其他社会和结构性因素推动的 决定因素。2021年国际会计准则将是关键的全球科学会议，以审查针对剩余的进展 在控制疫情方面的挑战。 预计将在IAS 2021上分享的重要新见解包括病毒学、免疫学的基础工作 和艾滋病毒的发病机制，继续把重点放在功能性治疗/缓解议程上。HIV的临床研究 正在进入一个长效和注射制剂的新时代，这将在2021年国际会计准则大会上得到强调， 剩下的挑战是坚持、服药疲劳和多药耐药变种。儿科临床护理 问题将是另一个关键话题，即基于整合酶抑制剂的婴儿和 儿童将成为主要关注的焦点。在预防领域，长效注射剂的优势被发现 作为PrEP的Cabotegravir标志着一个新时代的开始，预计IAS将在这方面提供更多证据 2021年，以及长效注射剂与其他产品联合配制的早期数据 避孕、阿片类药物依赖和其他健康状况。在实施科学领域创新 检测、预防、治疗和监测模式将在2021年国际会计准则会议上占据突出地位。最后， 新冠肺炎大流行预计将成为所有科学研究的主题之一，以对抗 世界各地治疗中断的背景以及关于艾滋病毒/SARS的许多剩余不确定性- 冠状病毒-2相互作用。 虽然IAS正在做出类似的规定，如果国家要求的话，可以转变为完全虚拟的交付格式 关于新冠肺炎大流行，2021年国际会计准则会议计划于2021年7月18日至21日在柏林举行，届时将产生强烈的 虚拟存在，以确保广泛访问(预计将有6,000名代表出席)。它将提供一个关键的 艾滋病毒科学平台在一个现在以庆祝多样性和零为特征的国家重新召开 歧视。柏林位于欧洲的中心，与欧洲艾滋病毒感染最严重的地区有着密切的联系。 欧洲--中欧和东欧，特别是乌克兰和俄罗斯联邦，在这些国家， 与德国相比，以权利为基础的艾滋病毒规划方法不断受到挑战。 《国际会计准则2021》的具体目标是： 1.加快基础科学和临床创新，促进以人为本的发展和应用， 艾滋病毒的精准医学，包括发病机制、传播、疫苗、缓解和功能治疗。 2.促进临床研究中的跨学科合作，改善所有生命阶段的综合护理 并加快更新治疗指南，特别是针对受感染的低收入和中等收入国家 儿童、艾滋病毒、结核病、病毒性肝炎和新冠肺炎感染者； 3.加强艾滋病毒预防研究，以改进生物医学、行为和结构干预措施以及 在预防方案中整合新工具，包括长效注射预防技术 有需要的人； 4.在艾滋病毒预防到护理级联中推进执行科学议程的核心组成部分 在新冠肺炎时代，包括融合方面和有意义社区的方法 参与卫生系统并为其提供资源； 5.在关键和边缘化人群中处理艾滋病毒脆弱性和疾病发展的决定因素， 包括减少污名和歧视的新干预措施和实施科学，包括 对艾滋病毒、其他疾病、同性恋恐惧症、跨性别恐惧症以及族裔和种族差异的跨部门污名。 科学计划将包括四个轨道：A轨道-基础科学；B轨道-临床科学；C轨道 -预防科学；以及跟踪D--社会、行为和实施科学。横切方面将 在全体会议上被覆盖，这些会议还将科学轨道与社区和领导层的观点联系起来， 衔接课程将跨越至少两个赛道，为多学科提供机会 对话。青年研究人员、基础科学家和非政府组织等相关领域研究人员的参与 将通过积极征集相关科学知识和提供 除了增加远程访问选项外，还提供具体的财务支持。